193 related articles for article (PubMed ID: 32315869)
1. Quality of life after switching from well-controlled vitamin K antagonist to direct oral anticoagulant: Little to GAInN.
van Miert JHA; Kooistra HAM; Veeger NJGM; Westerterp A; Piersma-Wichers M; Meijer K
Thromb Res; 2020 Jun; 190():69-75. PubMed ID: 32315869
[TBL] [Abstract][Full Text] [Related]
2. Switching from vitamin K antagonists to direct oral anticoagulants in non-valvular atrial fibrillation patients: Does low time in therapeutic range affect persistence?
Toorop MMA; Chen Q; Kruip MJHA; van der Meer FJM; Nierman MC; Faber L; Goede L; Cannegieter SC; Lijfering WM
J Thromb Haemost; 2022 Feb; 20(2):339-352. PubMed ID: 34779140
[TBL] [Abstract][Full Text] [Related]
3. Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy.
De Caterina R; Brüggenjürgen B; Darius H; Köhler S; Lucerna M; Pecen L; Renda G; Schilling RJ; Schliephacke T; Zamorano JL; Le Heuzey JY; Kirchhof P
Arch Cardiovasc Dis; 2018 Feb; 111(2):74-84. PubMed ID: 28942115
[TBL] [Abstract][Full Text] [Related]
4. Real-life experience of quality of life, treatment satisfaction, and adherence in patients receiving oral anticoagulants for atrial fibrillation.
Benzimra M; Bonnamour B; Duracinsky M; Lalanne C; Aubert JP; Chassany O; Aubin-Auger I; Mahé I
Patient Prefer Adherence; 2018; 12():79-87. PubMed ID: 29379275
[TBL] [Abstract][Full Text] [Related]
5. [Quality of life of elderly people on oral anticoagulant for atrial fibrillation: VKA versus direct oral anticoagulants].
Fareau S; Baumstarck K; Farcet A; Molines C; Auquier P; Retornaz F
Geriatr Psychol Neuropsychiatr Vieil; 2015 Mar; 13(1):45-54. PubMed ID: 25786423
[TBL] [Abstract][Full Text] [Related]
6. Continuous and minimally-interrupted direct oral anticoagulant are both safe compared with vitamin K antagonist for atrial fibrillation ablation: An updated meta-analysis.
Ha FJ; Barra S; Brown AJ; Begley DA; Grace AA; Agarwal S
Int J Cardiol; 2018 Jul; 262():51-56. PubMed ID: 29606512
[TBL] [Abstract][Full Text] [Related]
7. Development of a tool to identify patients' preference for vitamin K antagonist or direct oral anticoagulant therapy.
Zolfaghari S; Harenberg J; Froelich L; Wehling M; Weiss C
Semin Thromb Hemost; 2014 Feb; 40(1):121-8. PubMed ID: 24381153
[TBL] [Abstract][Full Text] [Related]
8. Using the Case-Crossover Design to Assess Short-Term Risks of Bleeding and Arterial Thromboembolism After Switching Between Oral Anticoagulants in a Population-Based Cohort of Patients With Atrial Fibrillation.
Hellfritzsch M; Wang SV; Grove EL; Gagne JJ; Hallas J; Pottegård A
Am J Epidemiol; 2020 Dec; 189(12):1467-1477. PubMed ID: 32639512
[TBL] [Abstract][Full Text] [Related]
9. Quality of Anticoagulation and Treatment Satisfaction in Patients with Non-Valvular Atrial Fibrillation Treated with Vitamin K Antagonist: Result from the KORean Atrial Fibrillation Investigation II.
Oh S; Kim JS; Oh YS; Shin DG; Pak HN; Hwang GS; Choi KJ; Kim JB; Lee MY; Park HW; Kim DK; Jin ES; Park J; Oh IY; Shin DH; Park HS; Kim JH; Kim NH; Ahn MS; Seo BJ; Kim YJ; Kang S; Lee J; Kim YH
J Korean Med Sci; 2018 Dec; 33(49):e323. PubMed ID: 30505257
[TBL] [Abstract][Full Text] [Related]
10. Direct oral anticoagulants versus vitamin K antagonists in real-world patients with nonvalvular atrial fibrillation. The FANTASIIA study.
Anguita Sánchez M; Bertomeu Martínez V; Ruiz Ortiz M; Cequier Fillat Á; Roldán Rabadán I; Muñiz García J; Badimón Maestro L; Esteve Pastor MA; Marín Ortuño F;
Rev Esp Cardiol (Engl Ed); 2020 Jan; 73(1):14-20. PubMed ID: 31160265
[TBL] [Abstract][Full Text] [Related]
11. Choosing between continuing vitamin K antagonists (VKA) or switching to a direct oral anticoagulant in currently well-controlled patients on VKA for atrial fibrillation: a randomised controlled trial (GAInN).
van Miert JHA; Kooistra HAM; Veeger NJGM; Westerterp A; Piersma-Wichers M; Meijer K
Br J Haematol; 2019 Aug; 186(3):e21-e23. PubMed ID: 30843186
[No Abstract] [Full Text] [Related]
12. Quality of INR control and switching to non-Vitamin K oral anticoagulants between women and men with atrial fibrillation treated with Vitamin K Antagonists in Spain. A population-based, real-world study.
García-Sempere A; Hurtado I; Bejarano-Quisoboni D; Rodríguez-Bernal C; Santa-Ana Y; Peiró S; Sanfélix-Gimeno G
PLoS One; 2019; 14(2):e0211681. PubMed ID: 30753227
[TBL] [Abstract][Full Text] [Related]
13. Periprocedural anticoagulation during left atrial ablation: interrupted and uninterrupted vitamin K-antagonists or uninterrupted novel anticoagulants.
Brinkmeier-Theofanopoulou M; Tzamalis P; Wehrkamp-Richter S; Radzewitz A; Merkel M; Schymik G; van Mark G; Bramlage P; Schmitt C; Luik A
BMC Cardiovasc Disord; 2018 Apr; 18(1):71. PubMed ID: 29703158
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Treatment Persistence with Dabigatran or Rivaroxaban versus Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Competing Risk Analysis in the French National Health Care Databases.
Maura G; Billionnet C; Alla F; Gagne JJ; Pariente A
Pharmacotherapy; 2018 Jan; 38(1):6-18. PubMed ID: 29028119
[TBL] [Abstract][Full Text] [Related]
15. The importance of time in therapeutic range in switching from vitamin K antagonist to non-vitamin K antagonist oral anticoagulants in atrial fibrillation.
Vinding NE; Bonde AN; Rørth R; Lamberts M; Olesen JB; Gislason GH; Torp-Pedersen C; Køber L; Fosbøl EL
Europace; 2019 Apr; 21(4):572-580. PubMed ID: 30508073
[TBL] [Abstract][Full Text] [Related]
16. No antiarrhythmic effect of direct oral anticoagulants versus vitamin K antagonists in paroxysmal atrial fibrillation patients undergoing catheter ablation.
Zweiker D; Manninger M; Sieghartsleitner R; Ebner J; Pratl B; Bisping E; Lercher P; von Lewinski D; Riedlbauer R; Rohrer U; Spronk HMH; Zirlik A; Schotten U; Scherr D
Int J Cardiol; 2021 May; 331():106-108. PubMed ID: 33508338
[TBL] [Abstract][Full Text] [Related]
17. [Coumarin or DOAC in frail elderly patients with atrial fibrillation?].
Joosten LPT; van Doorn S; Hemels MEW; Huisman MV; Rutten FH; Geersing GJ
Ned Tijdschr Geneeskd; 2024 Jan; 168():. PubMed ID: 38525862
[TBL] [Abstract][Full Text] [Related]
18. Patients on vitamin K treatment: is switching to direct-acting oral anticoagulation cost-effective? A target trial on a prospective cohort.
Aebersold H; Foster-Witassek F; Aeschbacher S; Beer JH; Blozik E; Blum M; Bonati L; Conte G; Coslovsky M; De Perna ML; Di Valentino M; Felder S; Huber CA; Moschovitis G; Mueller A; Paladini RE; Reichlin T; Rodondi N; Stauber A; Sticherling C; Szucs TD; Conen D; Kuhne M; Osswald S; Schwenkglenks M; Serra-Burriel M;
Open Heart; 2024 Jan; 11(1):. PubMed ID: 38302139
[TBL] [Abstract][Full Text] [Related]
19. Selection, management, and outcome of vitamin K antagonist-treated patients with atrial fibrillation not switched to novel oral anticoagulants. Results from the Dresden NOAC registry.
Michalski F; Tittl L; Werth S; Hänsel U; Pannach S; Sahin K; Weiss N; Beyer-Westendorf J
Thromb Haemost; 2015 Nov; 114(5):1076-84. PubMed ID: 25994496
[TBL] [Abstract][Full Text] [Related]
20. Patient perceptions of anticoagulant treatment with dabigatran or a vitamin K antagonist for stroke prevention in atrial fibrillation according to region and age: an exploratory analysis from the RE-SONANCE study.
Vinereanu D; Napalkov D; Bergler-Klein J; Benczur B; Ciernik M; Gotcheva N; Medvedchikov A; Põder P; Simić D; Skride A; Tang W; Trusz-Gluza M; Vesely J
J Thromb Thrombolysis; 2021 Nov; 52(4):1195-1206. PubMed ID: 33929686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
